Boston Scientific Corp.

  • Market Cap: Large Cap
  • Industry: Retailing
  • ISIN: US1011371077
USD
97.72
-0.85 (-0.86%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Boston Scientific Corp. stock-summary
stock-summary
Boston Scientific Corp.
Retailing
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.
Company Coordinates stock-summary
Company Details
300 BOSTON SCIENTIFIC WAY , MARLBOROUGH MA : 01752-1234
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 196 Schemes (38.17%)

Foreign Institutions

Held by 565 Foreign Institutions (23.08%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Michael Mahoney
Chairman of the Board, President, Chief Executive Officer
Mr. Edward Ludwig
Lead Independent Director
Ms. Nelda Connors
Independent Director
Mr. Charles Dockendorff
Independent Director
Mr. Yoshiaki Fujimori
Independent Director
Ms. Donna James
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
5,061 Million
(Quarterly Results - Jun 2025)
Net Profit:
795 Million
stock-summary
Industry

Retailing

stock-summary
Market cap

USD 188,709 Million (Large Cap)

stock-summary
P/E

86.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

5,509.01%

stock-summary
Debt Equity

0.48

stock-summary
Return on Equity

11.42%

stock-summary
Price to Book

8.42